NCT04504071 2025-09-08
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
Shanghai Chest Hospital
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT04394624 2025-06-06
CARMEN-LC04
Sanofi
Phase 2 Terminated
NCT04836728 2025-03-13
CCICC-002b
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Active not recruiting
NCT06517953 2024-07-25
IcomBine
Sun Yat-sen University
Phase 2 Recruiting
NCT06045767 2024-06-03
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
Tel Aviv Medical Center
Phase 2 Not yet recruiting
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT02443337 2020-12-09
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT03656094 2019-12-09
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
Samsung Medical Center
Phase 2 Unknown
NCT01703091 2019-09-30
A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01935154 2019-06-19
Efficacy Study of Vx001 Vaccine in NSCLC Patients
Vaxon Biotech
Phase 2 Completed
NCT01752023 2018-10-17
NA_00067809
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03240549 2017-08-07
Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease
Beijing Hospital
Phase 2 Unknown
NCT00701558 2016-06-24
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Completed